Darwin Global Management »

Biohaven shares owned by Darwin Global Management

Quarter-by-quarter ownership of Biohaven (BHVN) shares owned by Darwin Global Management from 13F filings

Historical chart of Darwin Global Management investment in Biohaven

Tip: Access up to 7 years of quarterly data

All positions including Biohaven held by Darwin Global Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Biohaven by Darwin Global Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $81M 1.5M 54.69

More positions owned by Darwin Global Management

Vaxcyte (PCVX)
Nuvalent Inc-a (NUVL)
Keros Therapeutics (KROS)
Biohaven (BHVN)
Alpine Immune Sciences (ALPN)
Beam Therapeutics (BEAM)
Apogee Therapeutics (APGE)
Xencor (XNCR)
Spyre Therapeutics Com New (SYRE)
Elevation Oncology (ELEV)
Tourmaline Bio (TRML)
Merck & Co (MRK)

View all positions for Darwin Global Management

Top funds holding Biohaven

Vanguard Group
Stifel Financial
BlackRock
Henderson Group
Suvretta Capital Management
T. Rowe Price Associates
RP Management
Adage Capital Partners GP
Perceptive Advisors
FMR
Geode Capital Management
Darwin Global Management
Citadel Advisors
Holocene Advisors
T. Rowe Price Investment Management

View all funds holding Biohaven